Abstract
For health preservation and reducing the risk of premature ageing and related metabolic diseases, human diet should include various traditional, organic and functional foods as well as therapeutics that support alimentary and other functions of gut microbiota. To create or restore the impaired human biocenoses, various targeted microecological techniques and methods are used (Table 1), with a focus on either prevention or treatment. In the longer term, these approaches can be used in microecological engineering of pregnant and breastfeeding mothers, as well as infants for sha** their targeted microbial ecology. It should be remembered that though the responses of the host-microbiota system to the implementation of different dietary and microecological agents are on the whole predictable, they can vary considerably from individual to individual as far as their focus, efficiency and distinct manifestations are concerned (Shenderov 2014b; Lenoir-Wijnkoop et al. 2007; Shenderov 2011b; Sonnenburg and Backhed 2016). Since 1950s, over 150 different microecological therapeutics have been developed and produced commercially for prevention and treatment of diseases related to the imbalance of symbiotic microbiota. To preserve and restore human microbial ecology, a wide range of microecological therapeutics are used (probiotics, symbiotics, combiotics, prebiotics, synbiotics, virobiotics (including phagobiotics), genetically engineered probiotics, metabiotics), as well as the technique of transplantation of large intestine microbiota.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Bibliography
Bengmark S. Nutrition and resistance to disease. In: Heidt PJ, Nieuwenhuis P, Rusch VD, van der Waaij D, editors. Old Herborn University Seminar Monographs 14: Intestinal translocation. Herborn Litterae: Herborn-Dill; 2001. p. 117–133.
Bik EM, Ugalde JA, Cousins J, Goddard AD, Richman J, Apte ZS. Microbial biotransformations in the human distal gut. British J Pharmacology. 2018;175(24):4404–4414. doi:https://doi.org/10.1111/bph.14085.
Browne HP, Forster SC, Anonye BO, Kumar N, Neville BA et al. Culturing of “unculturable” human microbiota reveals novel taxa and extensive sporulation. Nature. 2016;533:543–546. doi:https://doi.org/10.1038/nature17645.
Chervinets YuV, Chervinets VM, Shenderov BA. The modern view on the biotechnological potential of human symbiotic microbiota. Upper Volga medical journal. 2018;17(1):19–26 (in Russian).
Dore J, Simren M, Buttle L, Guarner F. Hot topics in gut microbiota. United Europ Gastroenterol J. 2013;1(5):311–318. doi:https://doi.org/10.1177/2050640613502477.
Engevik MA, Versalovic J. Biochemical feature of beneficial microbes: foundation for therapeutic microbiology. Microbial Spectr. 2017;5(5). doi:https://doi.org/10.1128/microbiolspec.BAD-0012-2016.
Lebeer S, Bron PA, Marco ML, Van Pijkeren JP, O’Conell Motherway M et al. Identification of probiotic effect or molecules: present state and future perspectives. Curr Opin Biotechnol. 2018;49:217–223. doi:https://doi.org/10.1016/j.copbio.2017.10.007.
Lebeer S, Vanderleyden J, De Keersmaeker SCJ. Genes and molecules of lactobacilli supporting probiotic action. Microbiol Mol Biol Rev. 2008;72(4):728–764. doi:https://doi.org/10.1128/MMBR.00017-08.
Lenoir-Wijnkoop I, Sanders ME, Cabana MD, Van Loo J, Sherman PM et al. Probiotic and probiotic influence beyond the intestinal tract. Nutr Rev. 2007;65(11):469–489. doi:https://doi.org/10.1111/j.1753-4887.2007.tb00272.x.
Maguire M, Maguire G. Gut dysbiosis, leaky gut, and intestinal epithelial proliferation in neurological disorders: towards the development of a new therapeutic using amino acids, prebiotics, probiotics, and postbiotics. Rev Neurosci. 2019;30(2):179–201. doi:https://doi.org/10.1515/revneuro-2018-0024.
Mimee M, Citorik RJ, Lu TK. Microbiome therapeutics-Advances and challenges. Adv Drug Deliv Rev. 2016;105(Pt A):44–54. doi:https://doi.org/10.1016/j.addr.2016.04.032.
Reid G, Younes JA, Mei Van der HC, Gloor GB et al. Microbiota restoration: natural and supplemented recovery of human microbial communities. Nat Rev Microbiol. 2011;9(1):27–38. doi:https://doi.org/10.1038/nrmicro2473.
Roberfroid M, Gibson GR, Hoyles L, McCartney AL et al. Prebiotic effects: metabolic and health benefits. Br J Nutr. 2010;104 Suppl 2:1–63. doi:https://doi.org/10.1017/S0007114510003363.
Shenderov BA. Functional nutrition and its role in the prevention of metabolic syndrome. Moscow: DeLi print; 2008 (in Russian).
Shenderov BA. Probiotic (symbiotic) bacterial languages. Anaerobe. 2011;17(6):490–495. doi:https://doi.org/10.1016/j.anaerobe.2011.05.009.
Sonnenburg JL, Backhed F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016;535(7610):56–64. doi:https://doi.org/10.1038/nature18846.
Suvorov A. Gut microbiota, probiotics, and human health. Bioscience of Microbiota, Food and Health. 2013;32(3):81–91. doi:https://doi.org/10.12938/bmfh.32.81.
Venema K, do Carmo AP. Probiotic and Prebiotics: Current Research and Future Trends. Wageningen: Caiser Academic Press; 2015. doi:https://doi.org/10.21775/9781910190098.
Vyas U, Ranganathan N. Probiotics, prebiotics, and synbiotics: gut and beyond. Gastroenterology Research and Practice. 2012;2012:872716. doi:https://doi.org/10.1155/2012/872716.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Shenderov, B.A., Sinitsa, A.V., Zakharchenko, M.M., Lang, C. (2020). Contemporary Microecological Strategies of Gut Microbiota Modulation for Human Health Preservation, Restoration and Improvement. In: METABIOTICS. Springer, Cham. https://doi.org/10.1007/978-3-030-34167-1_7
Download citation
DOI: https://doi.org/10.1007/978-3-030-34167-1_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-34166-4
Online ISBN: 978-3-030-34167-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)